Catalyst Biosciences
AcquiredGyre Therapeutics – Focused on organ fibrosis and inflammatory disease
South San Francisco, United States · Founded 2000 · $100.4M raised
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2000
- Business Model
- B2B
- Website
- catalystbiosciences.com
- Total Funding
- $100.4M
- Last Round
- $30.0M Corporate RoundJan 2011
- Rounds
- 3
About
Catalyst Biosciences was a South San Francisco-based biopharmaceutical company focused on developing protein therapeutics for rare bleeding disorders including hemophilia. In 2023, GC Biopharma acquired Catalyst's rare hematology pipeline assets while Catalyst completed a reverse merger with GNI Group's Beijing Continent Pharmaceuticals, pivoting to fibrosis treatments.
Summary
Catalyst Biosciences is a Biotech company based in South San Francisco, United States, founded in 2000. It has raised $100.4M in total across 3 rounds, most recently a $30.0M Corporate Round round in Jan 2011. Investors include Essex Woodlands Health Ventures, Burrill & Company and HealthCare.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2023
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...